【摘要】 目的分析HBeAg阴性慢性乙型肝炎(CHB)患者血清学指标与肝组织病理学的特点。方法回顾性对照分析HBeAg阴性CHB与HBeAg阳性CHB各125例患者血清ALT、HBV-DNA水平及肝脏病理组织分期分级的发病特点。结果 1HBeAg阳性组的总体HBV-DNA载量、ALT水平均高于HBeAg阴性组(P<0.05)。2HBV-DNA≥105IU/mL时,HBeAg阳性CHB的比例为80.8%(101/125),高于HBeAg阴性CHB的64.8%(81/125),P<0.05。ALT≥80U/mL时,HBeAg阳性CHB的比例为76.8%(96/125),显著高于HBeAg阴性CHB的56.8%(71/125),P<0.05。结论血清学指标能反映HBeAg阴性CHB患者的肝组织炎症和纤维化程度,HBV-DNA≥105IU/mL可能作为临界值成为HBeAg阴性CHB患者抗病毒治疗的重要依据。更多还原

【Abstract】 Objective To analyze the clinical features of serum markers and hepatic pathology of HBeAg-negative chronic hepatitis(CHB) patients. Methods 125 cases of HBeAg-negative CHB patients and 125 cases of HBeAg-positive CHB patients were analyzed retrospectively. The serum markers(HBV-DNA and ALT), and pathologic stages of hepatic inflammation activity were observed and compared. Results 1The overall HBV-DNA load and ALT level of HBeAg-positive CHB patients were significantly higher than those of HBeAg-negative CHB patients(both P <0.05). 2 When the HBV-DNA load ≥ 105IU/m L, the ratio of HBeAg-positive CHB was 80.8%(101/125), significantly higher than 64.8%(81/125) of HBeAg-negative CHB(P <0.05). When the ALT level ≥ 80 U/m L, the ratio of HBeAg-positive CHB was 76.8%(96/125), significantly higher than 56.8%(71/125) of HBeAg-negative CHB(P <0.05). Conclusions The serum markers can reflect the hepatic inflammation activity and fibrosis stage of HBeAg-negative CHB patients. HBV-DNA ≥ 105IU/m L maybe a critical value to evaluate if the antiviral therapy should be performed for HBeAg-negative CHB patients.更多还原